These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 9815852

  • 1. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases.
    Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O.
    Clin Cancer Res; 1997 Sep; 3(9):1623-8. PubMed ID: 9815852
    [Abstract] [Full Text] [Related]

  • 2. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
    Fan SQ, Wei QY, Li MR, Zhang LQ, Liang QC.
    Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients' survival in breast cancer.
    Nakopoulou L, Katsarou S, Giannopoulou I, Alexandrou P, Tsirmpa I, Panayotopoulou E, Mavrommatis J, Keramopoulos A.
    Mod Pathol; 2002 Jan; 15(1):26-34. PubMed ID: 11796838
    [Abstract] [Full Text] [Related]

  • 5. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success.
    Span PN, Lindberg RL, Manders P, Tjan-Heijnen VC, Heuvel JJ, Beex LV, Sweep CG.
    J Pathol; 2004 Apr; 202(4):395-402. PubMed ID: 15095266
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
    Wei QY, Wu YQ, Fan SQ.
    Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
    [Abstract] [Full Text] [Related]

  • 8. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K, Shigemasa K, Nagai N, Ohama K.
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [Abstract] [Full Text] [Related]

  • 9. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
    Hu XX, Li L, Li DR, Zhang W, Cheng XQ, Zhang JQ, Tang BJ.
    Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
    [Abstract] [Full Text] [Related]

  • 10. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
    Zhang YG, DU J, Tian XX, Zhong YF, Fang WG.
    Chin Med J (Engl); 2007 Sep 20; 120(18):1597-605. PubMed ID: 17908479
    [Abstract] [Full Text] [Related]

  • 11. Tumor tissue inhibitor of metalloproteinases-1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratification of prognosis together with nodal status.
    Kuvaja P, Hulkkonen S, Pasanen I, Soini Y, Lehtonen S, Talvensaari-Mattila A, Pääkkö P, Kaakinen M, Autio-Harmainen H, Hurskainen T, Lehenkari P, Turpeenniemi-Hujanen T.
    Exp Cell Res; 2012 Jun 10; 318(10):1094-103. PubMed ID: 22465225
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Measurement of ER and PR status in breast cancer using the QuantiGene2.0 assay.
    Chae BJ, Bae JS, Yim HW, Lee A, Song BJ, Jeon HM, Chun MH, Jung SS.
    Pathology; 2011 Apr 10; 43(3):248-53. PubMed ID: 21436635
    [Abstract] [Full Text] [Related]

  • 17. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
    de Candia P, Akram M, Benezra R, Brogi E.
    Hum Pathol; 2006 Aug 10; 37(8):1032-41. PubMed ID: 16867866
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.
    Breast Cancer Res Treat; 2009 Jul 10; 116(1):131-43. PubMed ID: 18668363
    [Abstract] [Full Text] [Related]

  • 20. Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas.
    Gakiopoulou H, Nakopoulou L, Siatelis A, Mavrommatis I, Panayotopoulou EG, Tsirmpa I, Stravodimos C, Giannopoulos A.
    Clin Cancer Res; 2003 Nov 15; 9(15):5573-81. PubMed ID: 14654538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.